Genialis Launches BioBridge to Help Derisk Global Drug Development of China-origin Oncology Drugs
Supermodel-powered platform translates tumor biology across patient populations, addressing a structural gap in East-to-West asset licensing
Genialis, the therapeutic intelligence company, today announced Genialis™ BioBridge to help pharmaceutical sponsors translate clinical results generated in Chinese patient populations into biomarker-ready assets for Western trials and regulatory submissions.
The global drug development landscape has shifted with many innovative oncology therapies now being discovered and clinically validated first in China before being licensed for development in North America and Europe. Chinese biopharma out-licensing reached $137.7 billion in 2025, driven by 157 deals — nearly three times the transaction volume of 2024. While these transactions provide Western sponsors with access to promising therapies, they also pose biological and regulatory challenges. Clinical efficacy signals, biomarker strategies, and patient response patterns observed in Chinese trials may not translate directly to Western patient populations.
Regulatory agencies, including the U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA), typically require evidence that therapeutic activity and biomarker performance remain robust across geographically diverse populations. BioBridge was built to help sponsors answer that question before launching costly global development programs.
